Tianjin Ringpu Bio-TechnologyLtd 過去の業績
過去 基準チェック /26
Tianjin Ringpu Bio-TechnologyLtd has been growing earnings at an average annual rate of 11%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 7.9% per year. Tianjin Ringpu Bio-TechnologyLtd's return on equity is 9.7%, and it has net margins of 17.6%.
主要情報
11.0%
収益成長率
6.9%
EPS成長率
| Pharmaceuticals 業界の成長 | 10.9% |
| 収益成長率 | 7.9% |
| 株主資本利益率 | 9.7% |
| ネット・マージン | 17.6% |
| 前回の決算情報 | 30 Sep 2024 |
最近の業績更新
Recent updates
These 4 Measures Indicate That Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119) Is Using Debt Reasonably Well
Oct 30
The Market Lifts Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) Shares 36% But It Can Do More
Oct 08Tianjin Ringpu Bio-Technology Co.,Ltd. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Aug 26Improved Earnings Required Before Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) Shares Find Their Feet
Aug 23Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119) Seems To Use Debt Quite Sensibly
Jun 26Impressive Earnings May Not Tell The Whole Story For Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119)
Apr 05Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Subdued P/E Might Signal An Opportunity
Mar 28収支内訳
Tianjin Ringpu Bio-TechnologyLtd の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Sep 24 | 2,409 | 424 | 564 | 183 |
| 30 Jun 24 | 2,354 | 434 | 564 | 179 |
| 31 Mar 24 | 2,339 | 460 | 563 | 177 |
| 31 Dec 23 | 2,249 | 453 | 555 | 172 |
| 30 Sep 23 | 2,195 | 387 | 548 | 182 |
| 30 Jun 23 | 2,170 | 385 | 531 | 160 |
| 31 Mar 23 | 2,136 | 355 | 518 | 143 |
| 01 Jan 23 | 2,084 | 347 | 507 | 132 |
| 30 Sep 22 | 1,985 | 354 | 555 | 105 |
| 30 Jun 22 | 1,875 | 349 | 530 | 113 |
| 31 Mar 22 | 1,838 | 369 | 511 | 114 |
| 01 Jan 22 | 2,007 | 413 | 547 | 117 |
| 30 Sep 21 | 2,038 | 438 | 522 | 124 |
| 30 Jun 21 | 2,117 | 454 | 548 | 120 |
| 31 Mar 21 | 2,106 | 441 | 552 | 116 |
| 31 Dec 20 | 2,000 | 398 | 551 | 111 |
| 30 Sep 20 | 1,895 | 302 | 549 | 102 |
| 30 Jun 20 | 1,737 | 255 | 527 | 97 |
| 31 Mar 20 | 1,613 | 224 | 495 | 94 |
| 31 Dec 19 | 1,467 | 194 | 440 | 94 |
| 30 Sep 19 | 1,346 | 158 | 399 | 89 |
| 30 Jun 19 | 1,260 | 137 | 373 | 84 |
| 31 Mar 19 | 1,203 | 124 | 373 | 79 |
| 31 Dec 18 | 1,190 | 119 | 360 | 80 |
| 30 Sep 18 | 1,179 | 108 | 371 | 81 |
| 30 Jun 18 | 1,157 | 117 | 301 | 123 |
| 31 Mar 18 | 1,112 | 112 | 321 | 105 |
| 31 Dec 17 | 1,047 | 105 | 343 | 85 |
| 30 Sep 17 | 1,008 | 136 | 341 | 61 |
| 30 Jun 17 | 993 | 138 | 402 | 0 |
| 31 Mar 17 | 988 | 140 | 398 | 0 |
| 31 Dec 16 | 970 | 133 | 391 | 0 |
| 30 Sep 16 | 943 | 129 | 357 | 0 |
| 30 Jun 16 | 905 | 113 | 364 | 0 |
| 31 Mar 16 | 832 | 108 | 337 | 0 |
| 31 Dec 15 | 793 | 110 | 334 | 0 |
| 30 Sep 15 | 690 | 68 | 330 | 0 |
| 30 Jun 15 | 639 | 43 | 340 | 0 |
| 31 Mar 15 | 625 | 34 | 346 | 0 |
| 31 Dec 14 | 585 | 27 | 327 | 0 |
| 30 Sep 14 | 669 | 95 | 323 | 0 |
| 30 Jun 14 | 676 | 113 | 304 | 0 |
| 31 Mar 14 | 722 | 140 | 299 | 0 |
| 31 Dec 13 | 755 | 152 | 302 | 0 |
質の高い収益: 300119 has a large one-off gain of CN¥177.5M impacting its last 12 months of financial results to 30th September, 2024.
利益率の向上: 300119's current net profit margins (17.6%) are lower than last year (17.7%).
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: 300119's earnings have grown by 11% per year over the past 5 years.
成長の加速: 300119's earnings growth over the past year (9.4%) is below its 5-year average (11% per year).
収益対業界: 300119 earnings growth over the past year (9.4%) exceeded the Pharmaceuticals industry -1.2%.
株主資本利益率
高いROE: 300119's Return on Equity (9.7%) is considered low.